A defect in GPI synthesis as a suggested mechanism for the role of ARV1 in intellectual disability and seizures.


Journal

Neurogenetics
ISSN: 1364-6753
Titre abrégé: Neurogenetics
Pays: United States
ID NLM: 9709714

Informations de publication

Date de publication:
10 2020
Historique:
received: 05 03 2020
accepted: 05 05 2020
pubmed: 29 5 2020
medline: 16 6 2021
entrez: 29 5 2020
Statut: ppublish

Résumé

Deficiency of the endoplasmic reticulum transmembrane protein ARV1 leads to epileptic encephalopathy in humans and in mice. ARV1 is highly conserved, but its function in human cells is unknown. Studies of yeast arv1 null mutants indicate that it is involved in a number of biochemical processes including the synthesis of sphingolipids and glycosylphosphatidylinositol (GPI), a glycolipid anchor that is attached to the C-termini of many membrane bound proteins. GPI anchors are post-translational modifications, enabling proteins to travel from the endoplasmic reticulum (ER) through the Golgi and to attach to plasma membranes. We identified a homozygous pathogenic mutation in ARV1, p.Gly189Arg, in two brothers with infantile encephalopathy, and characterized the biochemical defect caused by this mutation. In addition to reduced expression of ARV1 transcript and protein in patients' fibroblasts, complementation tests in yeast showed that the ARV1 p.Gly189Arg mutation leads to deficient maturation of Gas1, a GPI-anchored protein, but does not affect sphingolipid synthesis. Our results suggest, that similar to mutations in other proteins in the GPI-anchoring pathway, including PIGM, PIGA, and PIGQ, ARV1 p.Gly189Arg causes a GPI anchoring defect and leads to early onset epileptic encephalopathy.

Identifiants

pubmed: 32462292
doi: 10.1007/s10048-020-00615-4
pii: 10.1007/s10048-020-00615-4
doi:

Substances chimiques

ARV1 protein, human 0
Carrier Proteins 0
Glycosylphosphatidylinositols 0
Lipids 0
Membrane Proteins 0
PIGQ protein, human 0
phosphatidylinositol glycan-class A protein 0
Mannosyltransferases EC 2.4.1.-
PIGM protein, human EC 2.4.1.-

Types de publication

Case Reports Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

259-267

Subventions

Organisme : NIMH NIH HHS
ID : R01 MH083989
Pays : United States

Auteurs

Reeval Segel (R)

Medical Genetics Institute, Shaare Zedek Medical Center and Hebrew University-Hadassah School of Medicine, P.O.B. 3235, 91031, Jerusalem, Israel. Reevals@szmc.org.il.

Adi Aran (A)

Department of Pediatrics, Neuropediatrics Unit, Shaare Zedek Medical Center and Hebrew University-Hadassah School of Medicine, Jerusalem, Israel.

Suleyman Gulsuner (S)

Departments of Medicine and Genome Sciences, University of Washington, Seattle, WA, USA.

Hiroki Nakamura (H)

Graduate School of Biosphere Science, Hiroshima University, 1-4-4, Kagamiyama, Higashi-hiroshima, Hiroshima, 739-8528, Japan.

Tzvia Rosen (T)

Medical Genetics Institute, Shaare Zedek Medical Center and Hebrew University-Hadassah School of Medicine, P.O.B. 3235, 91031, Jerusalem, Israel.

Tom Walsh (T)

Departments of Medicine and Genome Sciences, University of Washington, Seattle, WA, USA.

Hiroto Denda (H)

Graduate School of Biosphere Science, Hiroshima University, 1-4-4, Kagamiyama, Higashi-hiroshima, Hiroshima, 739-8528, Japan.

Sharon Zeligson (S)

Medical Genetics Institute, Shaare Zedek Medical Center and Hebrew University-Hadassah School of Medicine, P.O.B. 3235, 91031, Jerusalem, Israel.

Katsuki Eto (K)

Graduate School of Biosphere Science, Hiroshima University, 1-4-4, Kagamiyama, Higashi-hiroshima, Hiroshima, 739-8528, Japan.

Rachel Beeri (R)

Medical Genetics Institute, Shaare Zedek Medical Center and Hebrew University-Hadassah School of Medicine, P.O.B. 3235, 91031, Jerusalem, Israel.

Haruka Okai (H)

School of Applied Biological Science, Hiroshima University, 1-4-4, Kagamiyama, Higashi-hiroshima, Hiroshima, 739-8528, Japan.

Mary-Claire King (MC)

Departments of Medicine and Genome Sciences, University of Washington, Seattle, WA, USA.

Ephrat Levy-Lahad (E)

Medical Genetics Institute, Shaare Zedek Medical Center and Hebrew University-Hadassah School of Medicine, P.O.B. 3235, 91031, Jerusalem, Israel.

Kouichi Funato (K)

Graduate School of Biosphere Science, Hiroshima University, 1-4-4, Kagamiyama, Higashi-hiroshima, Hiroshima, 739-8528, Japan. kfunato@hiroshima-u.ac.jp.

Paul Renbaum (P)

Medical Genetics Institute, Shaare Zedek Medical Center and Hebrew University-Hadassah School of Medicine, P.O.B. 3235, 91031, Jerusalem, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH